Polypharmacy (intake of≥ 5 drugs) is an important issue for patients with chronic diseases
such as multiple sclerosis (MS). We aimed to assess the prevalence of polypharmacy with …

Multiple sclerosis (MS) is the most prevalent immune-mediated disease affecting the central
nervous system. A treatment strategy with multiple therapies is a frequent clinical scenario …

Objectives: The consequences of polypharmacy (intake of≥ 5 drugs) are diverse, including
drug interactions, rising costs and side effects. Risk groups for polypharmacy are …

Background: Little is known about polypharmacy and multiple sclerosis (MS). Objectives: To
estimate polypharmacy prevalence in a population-based MS cohort and compare persons …

Background Multiple sclerosis (MS) affects about three times more women than men. Due to
variable MS courses, multiple therapies are necessary in clinical practice. Objective We …

Background Multiple sclerosis (MS) is an immune-mediated disease of the central nervous
system. Given the chronic and heterogenous nature of the disease, treatment with various …

Background The aim of this study was to examine the societal costs of polypharmacy in
patients with multiple sclerosis (MS). We therefore focused on the association between the …

Background: Studies of depression and anxiety in multiple sclerosis (MS) patients have
reported higher rates in MS patients than the general population. Objective: To estimate the …

Objective. Patients with multiple sclerosis (MS) are often suffering from neuropathic pain.
Antiepileptic drugs (AEDs) and tricyclic antidepressants (TCAs) are commonly used and are …

Abstract Purpose of Review Polypharmacy, the use of≥ 5 medications, is common in people
with multiple sclerosis and is associated with negative outcomes. The use of multiple …